Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib dose-regimen study in FGFR-altered urothelial cancer
2023-510273-34-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of erdafitinib in transitional cell carcinoma (TCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Best overall response rate and Pharmacokinetic parameters of midazolam, 1-OH-midazolam, and metformin. Planned start Apr 2015; status: authorised.
02
Drugs
erdafitinib
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-510273-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510273-34-00.